Patent ID: 6930103

Claim:
A method of inhibiting both angiotensin converting enzyme and neutral endopeptidase for treatment of a disease amenable to treatment with a compound that inhibits both angiotensin converting enzyme and neutral endopeptidase which comprises administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (II) wherein R 1 is hydrogen or acetyl; R 2 is hydrogen, —CH 2 O—C(O)C(CH 3 ) 3 , C 1 -C 4 -alkyl, aryl, —(C 1 -C 4 -alkyl)-aryl, or diphenylmethyl; X is —(CH 2 ) n wherein n is an integer 0 or 1, —S—, —O—, wherein R 3 is hydrogen, C 1 -C 4 -alkyl, aryl, or —(C 1 -C 4 -alkyl)-aryl; and R 4 is CF 3 , C 1 -C 10 -alkyl, aryl, or —(C 1 -C 4 -alkyl)-aryl; B 1 and B 2 are each independently hydrogen, hydroxy, or —OR 5 , wherein R 5 is C 1 -C 4 -alkyl, aryl, or —(C 1 -C 4 -alkyl)-aryl or, where B 1 and B 2 are attached to adjacent carbon atoms, B 1 and B 2 can be taken together with said adjacent carbon atoms to form a benzene ring or methylenedioxy, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the disease is selected from the group consisting of diabetic nephropathy, insulin resistance, diabetic neuropathy, diabetic retinopathy, myocardial infarction, cataracts, and diabetic cardiomyopathy.